DARZALEX SC 1800 mg/15 ml, injection solution

( ARTG ) DARZALEX is indicated for the treatment of patients: with newly diagnosed multiple myeloma: - who are eligible for autologous stem cell transplant. For use in combination with: bortezomib, thalidomide, and dexamethasone. - who are ineligible for autologous stem cell transplant. For use in combination with: bortezomib, melphalan and prednisone, or lenalidomide and dexamethasone. with relapsed or refractory multiple myeloma who have received: - at least one prior therapy. For use in combination with: bortezomib and dexamethasone, or lenalidomide and dexamethasone. carfilzomib and dexamethasone - at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are refractory to both a PI and an immunomodulatory agent. For use as: monotherapy.